Hemab Therapeutics Holdings . Common Stock Stock Forecast

Buy or Hold candidate since Jun 24, 2026 Gain 37.38%

The Hemab Therapeutics Holdings, Inc. Common stock price gained 3.89% on the last trading day (Monday, 13th Jul 2026), rising from $38.03 to $39.51. It has now gained 5 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 10.63% from a day low at $37.99 to a day high of $42.03. The price has risen in 6 of the last 10 days and is up by 22.06% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 160 thousand more shares were traded than the day before. In total, 366 thousand shares were bought and sold for approximately $14.45 million.

The stock has broken the very wide and strong rising the short-term trend up and an even stronger rate of rising is indicated. For any reaction back there will now be support on the roof on the current trend broken at $38.13, a level that may pose a second chance to hit a runner. According to fan-theory $47.96 will be the next possible trend-top level and thereby pose a resistance level that may not be broken at the first attempt.

COAG Signals & Forecast

Mostly positive signals in the chart today. The Hemab Therapeutics Holdings, Inc. Common stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $34.44 and $29.42. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Monday, July 06, 2026, and so far it has risen 31.83%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal.

Support, Risk & Stop-loss for Hemab Therapeutics Holdings, Inc. Common stock

On the downside, the stock finds support just below today's level from accumulated volume at $36.73 and $34.00. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Hemab Therapeutics Holdings, Inc. Common finds support just below today's level at $36.73. If this is broken, then the next support from accumulated volume will be at $34.00 and $29.97.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $4.04 between high and low, or 10.63%. For the last week, the stock has had daily average volatility of 11.29%.

Our recommended stop-loss: $38.03 (-3.74%) (This stock has very high daily movements and this gives very high risk. There is a buy signal from a pivot bottom found 5 days ago.)

Trading Expectations (COAG) For The Upcoming Trading Day Of Tuesday 14th

For the upcoming trading day on Tuesday, 14th we expect Hemab Therapeutics Holdings, Inc. Common Stock to open at $39.84, and during the day (based on 14 day Average True Range), to move between $37.84 and $41.18, which gives a possible trading interval of +/-$3.33 (+/-8.80%) up or down from last closing price. If Hemab Therapeutics Holdings, Inc. Common Stock takes out the full calculated possible swing range there will be an estimated 8.80% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $36.73, some $2.78 (7.04%) from the current price of $39.51, our system finds the risk reward attractive.

Is Hemab Therapeutics Holdings, Inc. Common Stock stock A Buy?

Several short-term signals are positive and the stock has broke the rising trend up, which indicates an even stronger rate of rising. We conclude that the current level may hold a buying opportunity as there is a fair chance for Hemab Therapeutics Holdings, Inc. Common stock to perform well in the short-term period.

Current score: 3.063 Buy Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on July 14, 2026 - $39.84 ( 0.84%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk